Search RNAC
Cartesian Therapeutics, Inc.
Nasdaq · CIK 1453687
Last close7.36
Daily change+0.14 (1.94%)
10 Years gain-98.35%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
RNAC · STANDARD
SIC 2834 · Pharmaceutical Preparations · Fiscal year end 1231
Fundamental
41.1Momentum
n/aAcceleration
n/aConfidence
62.0Annual Revenue12
Quarterly Revenue44
Annual CFO11
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth0.0 / 25
Quality14.1 / 25
Capital Efficiency0.0 / 20
Balance Sheet15.0 / 15
Shareholder Economics10.0 / 10
Forward Indicators0.0 / 5
Signals
Net debt reductionNet debt declined versus the comparison period.
Warnings
Heavy share dilution · HIGHDiluted share count increased 15.2812%.
Key Metrics
Revenue Growth TTM-100%OK
Revenue CAGR 3Y-84.66%OK
Gross Marginn/aMISSING
Operating Marginn/aMISSING
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROICn/aMISSING
Incremental Operating Margin 3Yn/aNOT_MEANINGFUL
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y15.28%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $400,000.00 | $2.80M | -$143.41M | -$73.94M | -$79.40M | 699.25% | -35,851.25% | -19,848.75% | n/a | 25.97M |
| 2025 FY Dec 31, 2024 | $38.28M | $38.91M | -$43.90M | -$23.67M | -$32.77M | 101.67% | -114.69% | -85.61% | n/a | 17.36M |
| 2024 FY Dec 31, 2023 | $26.00M | $26.00M | -$86.42M | -$51.16M | -$51.37M | 100% | -332.32% | -197.54% | n/a | 5.17M |
| 2023 FY Dec 31, 2022 | $110.78M | $110.78M | $14.54M | -$31.63M | -$32.83M | 100% | 13.12% | -29.64% | n/a | 145.87M |
| 2023 FY Dec 31, 2021 | $85.08M | $85.08M | -$4.60M | -$60.38M | -$61.47M | 100% | -5.4% | -72.25% | n/a | 114.33M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $0.00 | sum latest 4 fiscal quarters Revenue | OK | 0001453687-26-000101, 0001453687-25-000120 |
| Revenue Growth TTM | -100% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001453687-26-000101, 0001453687-25-000120 |
| Revenue CAGR 3Y | -84.66% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001453687-26-000064 |
| Revenue CAGR 5Y | -52.53% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001453687-26-000064 |
| Gross Profit CAGR 3Y | -70.66% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001453687-26-000064 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001453687-26-000101, 0001453687-25-000120 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001453687-26-000101 |
| Current Ratio | 7.48x | Current Assets / Current Liabilities | OK | derived |
| Cash / Debt | 2.79x | (Cash + Short-term Investments) / Total Debt | OK | 0001453687-26-000101 |
| Revenue per Diluted Share | $0.00 | Revenue / Diluted Shares | OK | 0001453687-26-000101, 0001453687-25-000120 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |
| Dividend Payout Ratio | n/a | Cash dividends paid / Net income | NOT_MEANINGFUL | 0001453687-26-000064 |
| Diluted EPS TTM | n/a | Net income TTM / Diluted shares | NOT_MEANINGFUL | 0001453687-26-000101 |